30 closest matches · ranked by relevance
Skin Closure of Surgical Incisions by Tissue Glue vs Suture
Primary: Wound Healing by Numerical Scales for Rubor Postoperative Day 2. — 0.516; 0.984 units on a scale
Heart Transplant
Primary: Survival — 76; 75 Participants — p=<0.0001
Heart Transplant
Primary: Patient Survival — 75 Participants
Brain Death · Heart Failure
Primary: Heart Transplanted — 230; 223 Participants — p=0.57
Liver Transplantation · Kidney Transplantation
Primary: Delayed Kidney Graft Function — 5; 7 Participants
Third Degree Burn · Burns · Wound Infection
Primary: Percent Autograft Take on Wounds Prepared by StrataGraft™ Skin Tissue. — 97.7; 96.7 Percent Area of Autograft Take (%)
Kidney Disease
Primary: Number of Participants With Live Kidney Donor Activation Events — 87; 86; 88; 5 Participants
Utilization, Health Care · Obesity
Primary: Emergency Department Utilization — 77; 305 Participants
Accelerated Phase Chronic Myelogenous Leukemia · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q)
Primary: Percentage of Patients Who Are Able to Receive at Least One DLI Treatment — 36 Participants
Organ Transplantation
Primary: Number of Organs Recovered Per Donor — 3.79; 3.60 organs recovered per donor — p=0.38
Liver Transplant Recipient · Living Donor (of the Respective Liver Transplant Recipient)
Primary: Number of Participants Who Experienced Grade 3 or Higher Adverse Events (AEs) Deemed Attributable to darTreg Infusion — 0 Participants
Leukemia, Acute Lymphocytic (ALL) · Leukemia, Myeloid, Acute(AML) · Leukemia, Myeloid, Chronic(CML)
Primary: Event-free Survival (EFS) — 54.8 Percentage of participants
Corneal Disease · Fuch's Dystrophy · Pseudophakic Corneal Edema
Primary: Graft Failure — 142; 82 participants
Acute Lymphoblastic Leukemia · Non Hodgkins Lymphoma · Myelodysplastic Syndrome
Primary: Engraftment Rate After Transplant — 100; 100 percentage of participants
Brain Death
Primary: Primary Outcome Measure is IL-6 Level — 565.5; 264.9 pg/ml
Cardiac Transplant Disorder
Primary: Hospital Choice — 4; 21; 34; 13 Participants
Liver Transplant · Liver Transplantation
Primary: The Percent of Participants Who Achieve Operational Tolerance 52 Weeks After Completion of Immunosuppression Withdrawal. — 16.4 Percent of Participants
Acute Lymphoblastic Leukemia · Acute Myelogenous Leukemia · Chronic Myelogenous Leukemia
Primary: Antibody Recall Response Rate — 0.167 proportion of participants
Tissue and Organ Procurement · Alcohol Abstinence
Primary: Designated Organ Donor Status on Driver's License — 67; 38 participants
Cardiac Transplant Disorder
Primary: Hospital Choice — 33; 47; 23; 2 Participants
Normal Female Volunteers
Primary: Identification of the Full Set of Y-chromosome Short Tandem Repeats in Each Bioopsy. — 3; 1; 0; 0 Participants
Malignant Diseases · Non-malignant Diseases
Primary: Number of Patients With Severe (Grade III/IV) Acute Graft vs Host Disease (GVHD) — 0 Participants
Living Donor Liver Transplantation
Primary: Proportion of Safety Events — 1 Participants
Cardiac Transplant Disorder
Primary: Hospital Choice — 64; 125; 163; 192 Participants
Living Donors · Nephrectomy · Kidney Transplantation
Primary: The Primary End Point of the Study Was the Mean/Median Number of Days Postsurgery Required for Each Group to Return to 100% Functioning Capacity. — 43; 45 days
Donor Site Complication
Primary: Percentage of Participants Who Had > 95 % Epithelialization at Day 10 — 0 percentage of participants
Chronic Myelogenous Leukemia · Acute Myelogenous Leukemia · Chronic Lymphocytic Leukemia
Primary: Survival and Non-relapse Mortality at Day +200 Using the Miltenyi Reagent System — 43; 4 participants
Poor Thymic Function · Immunodeficiency · Athymia
Primary: Survival Rate at End of 1 Year — 90.9 percentage of participants
Wound of Skin
Primary: Change of Pain on Harvesting of Skin at Donor Site. — 2.6 millimeters
Brain Death · Organ Donor · Pulmonary Edema
Primary: Donor Oxygenation — 49; 40 cmH2O — p=0.98